These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18426697)

  • 1. [Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients].
    Romá-Sánchez E; Poveda-Andrés JL; García-Pellicer J; Salavert-Lletí M; Jarque-Ramos I
    Farm Hosp; 2008; 32(1):7-17. PubMed ID: 18426697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
    Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
    Luong ML; Husain S; Rotstein C
    Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
    Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
    Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
    Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
    Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
    Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
    Selleslag D; Vogelaers D; Marbaix S
    Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
    Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
    Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
    Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
    Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
    Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
    J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
    Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
    BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic effects of aspergillosis management in high-risk patients.
    Leather H
    Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
    Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
    Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
    Garbino J; Schnetzler G; Roberts C
    Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.